Thus, the combination of anti-ERBB2 agents either with inhibitors against proteasome or NF-kB decreases NF-kB activation through the inhibition of IkB degradation and may represent a novel therapeutic approach to treat RANK-expressing ERBB2-positive BC [57]. This evidence concerns the gene TNFRSF11A and breast cancer.